東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

A Study of Innovation v. Competition : = How did Regulation affect Firm Behavior via the Hatch-Waxman Act?

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	A Study of Innovation v. Competition :/
其他題名:	How did Regulation affect Firm Behavior via the Hatch-Waxman Act?
作者:	Laternser, Christina.
面頁冊數:	1 online resource (245 pages)
附註:	Source: Dissertations Abstracts International, Volume: 84-02, Section: B.
Contained By:	Dissertations Abstracts International84-02B.
標題:	Patent law. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29330547click for full text (PQDT)
ISBN:	9798834053392

A Study of Innovation v. Competition : = How did Regulation affect Firm Behavior via the Hatch-Waxman Act?
Laternser, Christina.

A Study of Innovation v. Competition :How did Regulation affect Firm Behavior via the Hatch-Waxman Act? - 1 online resource (245 pages)

Source: Dissertations Abstracts International, Volume: 84-02, Section: B.

Thesis (Ph.D.)--University of Illinois at Chicago, 2022.

Includes bibliographical references

This dissertation examines the effects of the Hatch-Waxman Act on the pharmaceutical market's behavior. The aim is to evaluate if and how brand-name pharmaceutical companies and generic firms alter their behaviors after the Hatch-Waxman Act and whether the Hatch-Waxman Act was able to attain its goal of balancing innovation and competition. Chapter one focuses on the theoretical dynamic Stackelberg model and Chapter two looks at empirical results. Chapter one provides theoretical justification for Chapter two; in a dynamic Stackelberg type environment, firms adjust their strategies in the face of shocks, such as the Hatch-Waxman Act. In the Hatch-Waxman Act's wake, brand pharmaceutical companies adjust the number of patents protecting their inventions while generic firms are more likely and able to enter generic sub-drug markets. The evidence presented in the two chapters show that firms do adjust their behaviors and a closed form solution is possible under either open-loop and feedback solutions (under strict assumptions); the Hatch-Waxman Act induces brand-name pharmaceutical companies to adjust their patenting behavior in the presence of certain market exclusivities while generic firms are more likely to enter certain drug markets based on the number of patents protecting the drug.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798834053392Subjects--Topical Terms:

3168356
Patent law.
Subjects--Index Terms:

Hatch-Waxman ActIndex Terms--Genre/Form:

542853
Electronic books.

A Study of Innovation v. Competition : = How did Regulation affect Firm Behavior via the Hatch-Waxman Act?
LDR:02967nmm a2200481K 4500 001 2357115
005 20230512095905.5
006 m o d
007 cr mn ---uuuuu
008 241011s2022 xx obm 000 0 eng d
020 $a 9798834053392
035 $a (MiAaPQ)AAI29330547
035 $a (MiAaPQ)0799vireo3079Laternser
035 $a AAI29330547
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Laternser, Christina. $3 3697634
245 1 2 $a A Study of Innovation v. Competition : $b How did Regulation affect Firm Behavior via the Hatch-Waxman Act?
264 0 $c 2022
300 $a 1 online resource (245 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 84-02, Section: B.
500 $a Advisor: Casey, Marcus ; Roberts, Helen.
502 $a Thesis (Ph.D.)--University of Illinois at Chicago, 2022.
504 $a Includes bibliographical references
520 $a This dissertation examines the effects of the Hatch-Waxman Act on the pharmaceutical market's behavior. The aim is to evaluate if and how brand-name pharmaceutical companies and generic firms alter their behaviors after the Hatch-Waxman Act and whether the Hatch-Waxman Act was able to attain its goal of balancing innovation and competition. Chapter one focuses on the theoretical dynamic Stackelberg model and Chapter two looks at empirical results. Chapter one provides theoretical justification for Chapter two; in a dynamic Stackelberg type environment, firms adjust their strategies in the face of shocks, such as the Hatch-Waxman Act. In the Hatch-Waxman Act's wake, brand pharmaceutical companies adjust the number of patents protecting their inventions while generic firms are more likely and able to enter generic sub-drug markets. The evidence presented in the two chapters show that firms do adjust their behaviors and a closed form solution is possible under either open-loop and feedback solutions (under strict assumptions); the Hatch-Waxman Act induces brand-name pharmaceutical companies to adjust their patenting behavior in the presence of certain market exclusivities while generic firms are more likely to enter certain drug markets based on the number of patents protecting the drug.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Patent law. $3 3168356
650 4 $a Pharmaceutical sciences. $3 3173021
653 $a Hatch-Waxman Act
653 $a Pharmaceutical companies
653 $a Innovation
653 $a Market exclusivity
653 $a Generic firm
653 $a Brand-name pharmaceutical companies
653 $a Patents
653 $a market entry
653 $a Pharmaceutical market
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0501
690 $a 0310
690 $a 0505
690 $a 0572
690 $a 0562
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a University of Illinois at Chicago. $b Economics. $3 2094958
773 0 $t Dissertations Abstracts International $g 84-02B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29330547 $z click for full text (PQDT)